Afucosylation as a way to enhance the activity of therapeutic antibodies in ADCC was also tested for Pertuzumab, directed against the epidermal growth factor receptor (HER2), and applied in HER2-positive breast cancer therapy. Here, ERBB2 is linked to breast carcinoma.